| human | Q5 |
| P496 | ORCID iD | 0000-0002-1336-081X |
| P734 | family name | Baillargeon | Q21453536 |
| Baillargeon | Q21453536 | ||
| Baillargeon | Q21453536 | ||
| P735 | given name | Jean-Patrice | Q44144529 |
| Jean-Patrice | Q44144529 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q35120058 | A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills |
| Q37600914 | Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status |
| Q37515575 | Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome |
| Q36958256 | Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity |
| Q39632808 | Age differences in expectations and readiness regarding lifestyle modifications in individuals at high risk of diabetes |
| Q39198717 | Alanine Aminotransferase Is a Marker of Lipotoxicity Consequences and Hyperandrogenemia in Women with Polycystic Ovary Syndrome |
| Q28294415 | Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome |
| Q36334951 | Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome |
| Q41818299 | Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats |
| Q51131411 | Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome. |
| Q34409440 | Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis |
| Q34013489 | Basic infertility including polycystic ovary syndrome |
| Q85029538 | Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro |
| Q42482678 | CSII: Longer Catheter Usage Time, a Reasonable Goal |
| Q44621360 | Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice |
| Q36303511 | Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? |
| Q34351640 | Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study |
| Q39967734 | Effectiveness of a multidisciplinary program for management of obesity: the Unité d'Enseignement, de Traitement et de Recherche sur l'Obésité (UETRO) database study |
| Q28271889 | Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome |
| Q45105542 | Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity |
| Q34229170 | Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial |
| Q42845705 | Erratum to: Impact of an integrated obesity management system on patient's care - research protocol |
| Q41111951 | Evolution of metabolic alterations 5 Years after early puberty in a cohort of girls predisposed to polycystic ovary syndrome |
| Q37445227 | Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases |
| Q42845707 | Gestational diabetes mellitus: simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose: comment on agarwal, dhatt, and shah |
| Q37310914 | Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism |
| Q34896686 | Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity |
| Q35718394 | Impact of an integrated obesity management system on patient's care - research protocol |
| Q47174891 | Improved cardiac function and dietary fatty acid metabolism after modest weight loss in subjects with impaired glucose tolerance |
| Q37355746 | Insulin and hyperandrogenism in women with polycystic ovary syndrome |
| Q35155109 | Insulin sensitizers for polycystic ovary syndrome |
| Q36951616 | Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome |
| Q33302215 | Integrated obesity care management system -implementation and research protocol |
| Q35496158 | Intergenerational cycle of obesity and diabetes: how can we reduce the burdens of these conditions on the health of future generations? |
| Q39777252 | Metabolically healthy obese women and functional capacity |
| Q44723070 | Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome |
| Q46938213 | Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction |
| Q34011558 | Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial |
| Q46561618 | On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans |
| Q37826425 | Oral hypoglycemic agents for gestational diabetes mellitus? |
| Q38268267 | PCOS in adolescence and type 2 diabetes |
| Q37031287 | PPARGC1α gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns |
| Q36822655 | Pilot study: can older inactive adults learn how to reach the required intensity of physical activity guideline? |
| Q47422495 | Predictors of success to weight-loss intervention program in individuals at high risk for type 2 diabetes |
| Q44851465 | Prevalence and predictors of vitamin D insufficiency in women of reproductive age living in northern latitude |
| Q44757155 | Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy |
| Q35864473 | Regional Brain Glucose Hypometabolism in Young Women with Polycystic Ovary Syndrome: Possible Link to Mild Insulin Resistance |
| Q40945617 | Regulation of blood flow in adipose tissue: involvement of the cholinergic system |
| Q36897081 | Risk of type 2 diabetes and cumulative excess weight exposure in the Framingham Offspring Study |
| Q55403020 | Role of Lipotoxicity and Contribution of the Renin-Angiotensin System in the Development of Polycystic Ovary Syndrome. |
| Q37355743 | Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity |
| Q37360333 | Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells |
| Q35688517 | Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome |
| Q35860762 | The Obesity-Fertility Protocol: a randomized controlled trial assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women |
| Q40778501 | The increase in serum 25-hydroxyvitamin D following weight loss does not contribute to the improvement in insulin sensitivity, insulin secretion and β-cell function |
| Q34161009 | Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome |
| Q35117211 | Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome |
| Q36301404 | Use of insulin sensitizers in polycystic ovarian syndrome. |
Search more.